Cardiac Pathways gets go-ahead for ablation catheters:
This article was originally published in Clinica
Executive Summary
Cardiac Pathways has received pre-market approval (PMA) for its Chillirpm cooled ablation catheters, including the company's Real-time Position Management navigation technology. The device includes a bi-directional steering capability and integrates the company's ultrasound transducer technology for dynamic real-time catheter navigation and visualisation. The PMA provides the additional approval necessary to use the RPM technology for therapy, the Sunnyvale, California-based company said.
You may also be interested in...
EU Health Ministers To Deliberate Over Commission’s Pharma Strategy
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.
Latest Vascepa Lawsuit Plunges Hikma Into Induced Infringement Battle
Hikma has pushed back against a further attempt by Amarin to counter its US generic version of Vascepa, this time via a fresh lawsuit claiming that the generic induces infringement of patents protecting cardiovascular indications for which the brand is approved but which are carved out of the generic label.
EU Approval Of COVID-19 Vaccines Possible In Weeks
The European Medicines Agency will continue working over the Christmas period so that it can complete its assessment of the newly filed marketing applications for BioNTech/Pfizer’s and Moderna’s COVID-19 vaccines as soon possible.
Need a specific report? 1000+ reports available
Buy Reports